CN108472269B - 具有改进的性质药学上可接受的β-胍基丙酸盐及其用途 - Google Patents

具有改进的性质药学上可接受的β-胍基丙酸盐及其用途 Download PDF

Info

Publication number
CN108472269B
CN108472269B CN201680057402.2A CN201680057402A CN108472269B CN 108472269 B CN108472269 B CN 108472269B CN 201680057402 A CN201680057402 A CN 201680057402A CN 108472269 B CN108472269 B CN 108472269B
Authority
CN
China
Prior art keywords
gpa
salt
pharmaceutically acceptable
fumarate
beta
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201680057402.2A
Other languages
English (en)
Chinese (zh)
Other versions
CN108472269A (zh
Inventor
E.J.马丁内斯
A.G.格里尔
A.辛赫
P.卡武鲁
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Insbona
Inspirna Inc
Original Assignee
Insbona
Rgenix Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Insbona, Rgenix Inc filed Critical Insbona
Priority to CN202111189796.6A priority Critical patent/CN114057611A/zh
Publication of CN108472269A publication Critical patent/CN108472269A/zh
Application granted granted Critical
Publication of CN108472269B publication Critical patent/CN108472269B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C277/00—Preparation of guanidine or its derivatives, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C277/08—Preparation of guanidine or its derivatives, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups of substituted guanidines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C279/04—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton
    • C07C279/14—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton being further substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/41—Preparation of salts of carboxylic acids
    • C07C51/412—Preparation of salts of carboxylic acids by conversion of the acids, their salts, esters or anhydrides with the same carboxylic acid part
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/42—Separation; Purification; Stabilisation; Use of additives
    • C07C51/43—Separation; Purification; Stabilisation; Use of additives by change of the physical state, e.g. crystallisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13—Dicarboxylic acids
    • C07C57/15—Fumaric acid

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CN201680057402.2A 2015-08-25 2016-08-25 具有改进的性质药学上可接受的β-胍基丙酸盐及其用途 Active CN108472269B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202111189796.6A CN114057611A (zh) 2015-08-25 2016-08-25 具有改进的性质药学上可接受的β-胍基丙酸盐及其用途

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562209624P 2015-08-25 2015-08-25
US62/209624 2015-08-25
PCT/US2016/048643 WO2017035331A1 (en) 2015-08-25 2016-08-25 PHARMACEUTICALLY ACCEPTABLE SALTS OF β-GUANIDINOPROPIONIC ACID WITH IMPROVED PROPERTIES AND USES THEREOF

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202111189796.6A Division CN114057611A (zh) 2015-08-25 2016-08-25 具有改进的性质药学上可接受的β-胍基丙酸盐及其用途

Publications (2)

Publication Number Publication Date
CN108472269A CN108472269A (zh) 2018-08-31
CN108472269B true CN108472269B (zh) 2021-11-02

Family

ID=58100994

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201680057402.2A Active CN108472269B (zh) 2015-08-25 2016-08-25 具有改进的性质药学上可接受的β-胍基丙酸盐及其用途
CN202111189796.6A Pending CN114057611A (zh) 2015-08-25 2016-08-25 具有改进的性质药学上可接受的β-胍基丙酸盐及其用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202111189796.6A Pending CN114057611A (zh) 2015-08-25 2016-08-25 具有改进的性质药学上可接受的β-胍基丙酸盐及其用途

Country Status (16)

Country Link
US (4) US20170056352A1 (enExample)
EP (1) EP3340973B1 (enExample)
JP (2) JP6880023B2 (enExample)
KR (1) KR102707964B1 (enExample)
CN (2) CN108472269B (enExample)
AU (1) AU2016311368B2 (enExample)
CA (1) CA2996520C (enExample)
DK (1) DK3340973T3 (enExample)
ES (1) ES2843561T3 (enExample)
HR (1) HRP20210044T1 (enExample)
HU (1) HUE053963T2 (enExample)
PL (1) PL3340973T3 (enExample)
PT (1) PT3340973T (enExample)
RS (1) RS61804B1 (enExample)
SI (1) SI3340973T1 (enExample)
WO (1) WO2017035331A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3137447B1 (en) 2014-04-30 2021-06-30 Rgenix, Inc. Inhibitors of creatine transport and uses thereof
WO2016100619A2 (en) * 2014-12-17 2016-06-23 Rgenix, Inc. Treatment and diagnosis of cancer
US20170056352A1 (en) * 2015-08-25 2017-03-02 Rgenix, Inc. PHARMACEUTICALLY ACCEPTABLE SALTS OF beta-GUANIDINOPROPIONIC ACID WITH IMPROVED PROPERTIES AND USES THEREOF
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
WO2018160178A1 (en) * 2017-03-01 2018-09-07 Rgenix, Inc. Pharmaceutically acceptable salts of b-guanidinopropionic acid with improved properties and uses thereof
EP3713575A4 (en) 2017-11-21 2021-08-25 Rgenix, Inc. POLYMORPHS AND THEIR USES
CA3161341A1 (en) 2019-12-11 2021-06-17 Masoud Fakhr Tavazoie Methods of treating cancer
JP7689964B2 (ja) 2019-12-13 2025-06-09 インスピルナ，インコーポレーテッド 金属塩及びその使用
KR102615692B1 (ko) 2021-10-13 2023-12-19 주식회사 휴엔켐 베타-구아니디노프로피온산을 포함하는 간섬유화 예방 또는 치료용 조성물
EP4511349A1 (en) * 2022-04-21 2025-02-26 Merck Sharp & Dohme LLC Process for preparing agglomerated crystalline medium-chain fatty acid sodium salts
KR102822799B1 (ko) 2022-11-09 2025-06-20 충남대학교산학협력단 베타-구아니디노프로피온산을 포함하는 장내 미생물 개선용 조성물

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3933797A (en) * 1972-02-22 1976-01-20 Pfizer Inc. 6-[α-(ω-QUANIDINOALKANOYLAMIDO)ACYLAMIDO]PENICILLANIC ACIDS
EP0426100A1 (en) * 1989-10-31 1991-05-08 Abbott Laboratories Stabilized enzyme compositions
US6329545B1 (en) * 1994-11-23 2001-12-11 Scott D. Larsen Aminoguanidine carboxylates for the treatment of non-insulin-dependent diabetes mellitus
CN102850242A (zh) * 2011-06-27 2013-01-02 天津天成制药有限公司 胍基丙酸硝酸盐的制备方法
CN103288685A (zh) * 2013-07-03 2013-09-11 郭礼强 一种3-胍基丙酸的制备方法
WO2014071067A2 (en) * 2012-10-31 2014-05-08 The Rockefeller University Treatment and diagnosis of colon cancer

Family Cites Families (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA101653A (en) 1906-08-30 1906-10-23 Herman Besser Mould
BE794886A (fr) * 1972-02-22 1973-08-02 Pfizer Acides 6-(alpha-(omega-guanidinoalcanoylamino)acylamino)-penicillaniques
US3972872A (en) 1974-09-23 1976-08-03 Pfizer Inc. 6-[α-(ω-Guanidinoalkanoylamido)acylamido]penicillanic acids
KR960004900B1 (ko) 1986-09-10 1996-04-17 신텍스(유.에스.에이.) 인코포레이티드 디아민의 선택적 아미딘화 방법
US5676978A (en) * 1989-02-14 1997-10-14 Amira, Inc. Methods of inhibiting undesirable cell growth using a combination of a cyclocreatine compound and a hyperplastic inhibitory agent
DE4334639A1 (de) 1993-10-11 1995-04-13 Inst Neue Mat Gemein Gmbh Verfahren zur Herstellung von TiN-Sinterkörpern und -Schichten
US5994577A (en) 1994-11-23 1999-11-30 Larsen; Scott D. Aminoguanidine carboxylates for the treatment of non-insulin-dependent diabetes mellitus
JP3745439B2 (ja) 1995-07-06 2006-02-15 花王株式会社 皮膚外用剤
TW453881B (en) 1995-10-16 2001-09-11 Kao Corp Cosmetic composition comprising amide derivatives
JPH09202710A (ja) * 1995-11-20 1997-08-05 Kao Corp しわ改善剤
EP0912523A1 (en) 1996-05-21 1999-05-06 PHARMACIA & UPJOHN COMPANY Aminoguanidine carboxylate lactams for the treatment of non-insulin-dependent diabetes mellitus
JP4317599B2 (ja) 1996-06-26 2009-08-19 武田薬品工業株式会社 徐放性製剤
DK1093370T3 (da) 1998-06-30 2006-05-22 Takeda Pharmaceutical Farmaceutisk præparat til behandling af diabetes
EP1656945A1 (en) 1999-06-05 2006-05-17 The Board Of Trustees Of The Leland Stanford Junior University Pharmaceutical composition comprising oligoarginine
US6605115B1 (en) 1999-06-05 2003-08-12 Board Of Trustees Of The Leland Stanford Junior University Method and composition for inhibiting cardiovascular cell proliferation
US6242491B1 (en) 1999-06-25 2001-06-05 Rima Kaddurah-Daouk Use of creatine or creatine compounds for skin preservation
US20020082448A1 (en) 1999-11-08 2002-06-27 The Upjohn Company Aminoguanidine carboxylates for the treatment of non-insulin-dependent diabetes mellitus
CA2456964A1 (en) 2001-08-08 2003-02-20 Merck & Co., Inc. Melanin-concentrating hormone antagonists
JP2005518346A (ja) 2001-11-07 2005-06-23 メディカル リサーチ カウンセル ドパミン作動性ニューロンの調節
CA2473229A1 (en) 2002-01-09 2003-07-24 Merck & Co., Inc. Selective melanin-concentrating hormone type -1 receptor agonists
US20120245211A1 (en) 2002-06-04 2012-09-27 Children's Hospital Medical Center Methods of Treating Cognitive Dysfunction by Modulating Brain Energy Metabolism
EP1567180A4 (en) 2002-06-04 2010-03-10 Avicena Group Inc METHOD FOR THE TREATMENT OF COGNITIVE DYSFUNCTION BY MODULATING THE CHANGE OF ENERGY REPLACEMENT IN THE BRAIN
GB0302882D0 (en) 2003-02-07 2003-03-12 Univ Cardiff Improvements in or relating to agents for the treatment of cardiovascular dysfunction and weight loss
EP1746099A1 (en) 2004-12-23 2007-01-24 DeveloGen Aktiengesellschaft Mnk1 or Mnk2 inhibitors
JP4865251B2 (ja) 2005-05-09 2012-02-01 株式会社 資生堂 不全角化抑制剤、毛穴縮小剤及び皮膚外用組成物
EP1909601B1 (de) 2005-08-02 2013-05-22 AlzChem Trostberg GmbH Flüssig-formulierung auf basis einer guanidinoessigsäure-komponente
WO2008054544A2 (en) 2006-05-22 2008-05-08 Immune Disease Institute, Inc. Method for delivery across the blood brain barrier
WO2008043024A2 (en) 2006-10-04 2008-04-10 Kalypsys, Inc. Oral pharmaceutical formulation comprising a sulfonyl bicyclic modulator of ppar for the treatment of disease
BRPI0720105A2 (pt) 2006-12-11 2014-10-07 Kempharm Inc Conjugados de aminoácido não padrões de anfetamina e processos para fabricação e uso dos mesmos
DE102007004781A1 (de) 2007-01-31 2008-08-07 Alzchem Trostberg Gmbh Verwendung von Guanidinoessigsäure(-Salzen) zur Herstellung eines gesundheitsfördernden Mittels
BRPI0807157A2 (pt) 2007-02-08 2014-04-29 Kempharm Inc Pró-farmacos hidrófilos polares de anfetamina e outros estimulantes e processos para fabricação e uso dos mesmos
EP2197890A1 (en) 2007-09-07 2010-06-23 Gencia Corporation Mitochondrial compositions and uses thereof
WO2009098142A1 (en) 2008-02-06 2009-08-13 Helm Ag Prasugrel salts with improved properties
FR2940077B1 (fr) 2008-12-19 2012-07-20 Oreal Procede de coloration eclaircissante de matieres keratiniques mettant en oeuvre une composition anhydre colorante comprenant un agent alcalin et une composition oxydante.
JP5711883B2 (ja) 2008-12-19 2015-05-07 ロレアル 脂肪物質に富む水性組成物の存在下で、淡色化し、あるいは淡色化直接染色し、あるいは酸化染色する方法、及びそのためのデバイス
FR2940104B1 (fr) 2008-12-19 2011-08-19 Oreal Procede de traitement des cheveux mettant en oeuvre une emulsion directe comprenant un agent oxydant et une composition contenant un agent alcalin
JP5866137B2 (ja) 2009-04-30 2016-02-17 ロレアル アミノトリアルコキシシランまたはアミノトリアルケニルオキシシラン化合物を含む組成物を用いたヒトケラチン繊維の明色化および／または着色ならびに装置
WO2011031308A1 (en) 2009-09-09 2011-03-17 Cytokinetics, Incorporated Novel combinations
EP2477643A1 (en) 2009-09-18 2012-07-25 Novo Nordisk A/S Long-acting y2 receptor agonists
FR2954160B1 (fr) 2009-12-22 2012-03-30 Oreal Composition de coloration ou d'eclaircissement comprenant un corps gras et un polymere amphotere
CA2785846C (en) 2009-12-31 2015-07-07 Kempharm, Inc. Amino acid conjugates of quetiapine, process for making and using the same
DE102010012199A1 (de) 2010-03-19 2011-09-22 Fresenius Medical Care Deutschland Gmbh Molekular geprägte Polymere für die Eliminierung von Metaboliten
FR2958161B1 (fr) 2010-04-02 2012-04-27 Oreal Procede de traitement des cheveux mettant en oeuvre une emulsion directe comprenant un agent oxydant et une emulsion directe contenant un agent alcalin
ES2713873T3 (es) 2010-04-16 2019-05-24 Nuevolution As Complejos bifuncionales y métodos para hacer y utilizar tales complejos
US20110262359A1 (en) 2010-04-21 2011-10-27 Jenkins Thomas E Compositions comprising enzyme-cleavable prodrugs of active agents and inhibitors thereof
US20110262355A1 (en) 2010-04-21 2011-10-27 Jenkins Thomas E Compositions comprising enzyme-cleavable opioid prodrugs and inhibitors thereof
EP2560490A1 (en) 2010-04-21 2013-02-27 Signature Therapeutics, Inc. Compositions comprising enzyme-cleavable prodrugs of active agents and inhibitors thereof
EP2560489A4 (en) 2010-04-21 2014-01-22 Signature Therapeutics Inc COMPOSITIONS WITH ENZYMSPALTBAR OPIOID PRODRUGS AND HEMMER FOR THIS
WO2011133348A1 (en) 2010-04-21 2011-10-27 Pharmacofore, Inc. Compositions comprising enzyme-cleavable amphetamine prodrugs and inhibitors thereof
RU2012151500A (ru) 2010-05-03 2014-06-10 Дженентек, Инк. Композиции и способы, пригодные для снижения вязкости белковосодержащих составов
US20130281410A1 (en) 2010-05-13 2013-10-24 University Of Utah Research Foundation Methods for the treatment of psychiatric disorders
EP2399885A1 (en) 2010-06-22 2011-12-28 Ulrich Dietz Device and method for solubilizing, separating, removing and reacting carboxylic acids in aqueous or organic solutions by means of micro- or nanoemulsification
WO2012024611A1 (en) 2010-08-20 2012-02-23 Natural Alternatives International, Inc. Methods of treating sarcopenia and frailty
WO2012047630A2 (en) 2010-09-27 2012-04-12 Martin Teintze N-alkyl or n-aryl substituted guanide and biguanide compounds and methods of their use
US8765115B2 (en) 2010-12-01 2014-07-01 National Institute of Agrobiological Scienses Method of treatment of gastrointestinal disorders with IL-10
BR112013022946A2 (pt) 2011-03-09 2017-07-18 Signature Therapeutics Inc pró-fármacos de agentes ativos com ligantes heterocíclocos
WO2012122420A2 (en) 2011-03-09 2012-09-13 Pharmacofore, Inc. Opioid prodrugs with heterocyclic linkers
US20120232066A1 (en) 2011-03-09 2012-09-13 Jenkins Thomas E Compositions for reducing risk of adverse events caused by drug-drug interactions
WO2012138214A1 (en) 2011-04-08 2012-10-11 Brewster Lizzy Maritza Beta-guanidinopropionic acid for the treatment of hypertension
WO2012173846A2 (en) 2011-06-06 2012-12-20 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
US8427223B2 (en) 2011-07-19 2013-04-23 Lsi Corporation Voltage level translator circuit for reducing jitter
MY162499A (en) 2011-07-28 2017-06-15 Kempharm Inc Methylphenidate-prodrugs, processes of making and using the same
CN104039342A (zh) 2011-10-18 2014-09-10 爱勒让治疗公司 拟肽大环化合物
FR2983407B1 (fr) 2011-12-06 2014-01-03 Oreal Composition aqueuse riche en huile et son utilisation dans un procede de coloration d'oxydation ou de decoloration
NZ627528A (en) 2012-02-15 2016-05-27 Aileron Therapeutics Inc Peptidomimetic macrocycles
HK1205454A1 (en) 2012-02-15 2015-12-18 Aileron Therapeutics, Inc. Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles
AU2013273138B2 (en) 2012-06-05 2017-06-15 Neuroderm Ltd Compositions comprising apomorphine and organic acids and uses thereof
WO2013189910A1 (en) 2012-06-22 2013-12-27 Basf Se Multicomponent crystals comprising imatinib mesilate and selected co-crystal formers
FR2997846B1 (fr) 2012-11-09 2023-10-20 Oreal Composition comprenant un derive dicarbonyle et un acide, le procede de lissage des fibres keratiniques a partir de cette composition
WO2014138492A1 (en) 2013-03-08 2014-09-12 Solan, LLC Methods for fabricating graphite-based structures and devices made therefrom
US20170056352A1 (en) 2015-08-25 2017-03-02 Rgenix, Inc. PHARMACEUTICALLY ACCEPTABLE SALTS OF beta-GUANIDINOPROPIONIC ACID WITH IMPROVED PROPERTIES AND USES THEREOF
WO2018160178A1 (en) 2017-03-01 2018-09-07 Rgenix, Inc. Pharmaceutically acceptable salts of b-guanidinopropionic acid with improved properties and uses thereof

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3933797A (en) * 1972-02-22 1976-01-20 Pfizer Inc. 6-[α-(ω-QUANIDINOALKANOYLAMIDO)ACYLAMIDO]PENICILLANIC ACIDS
EP0426100A1 (en) * 1989-10-31 1991-05-08 Abbott Laboratories Stabilized enzyme compositions
US6329545B1 (en) * 1994-11-23 2001-12-11 Scott D. Larsen Aminoguanidine carboxylates for the treatment of non-insulin-dependent diabetes mellitus
CN102850242A (zh) * 2011-06-27 2013-01-02 天津天成制药有限公司 胍基丙酸硝酸盐的制备方法
WO2014071067A2 (en) * 2012-10-31 2014-05-08 The Rockefeller University Treatment and diagnosis of colon cancer
CN103288685A (zh) * 2013-07-03 2013-09-11 郭礼强 一种3-胍基丙酸的制备方法

Also Published As

Publication number Publication date
CN114057611A (zh) 2022-02-18
JP6880023B2 (ja) 2021-06-02
ES2843561T3 (es) 2021-07-19
DK3340973T3 (da) 2021-01-11
AU2016311368A1 (en) 2018-03-29
HUE053963T2 (hu) 2021-07-28
US9827217B2 (en) 2017-11-28
KR102707964B1 (ko) 2024-09-20
AU2016311368B2 (en) 2020-10-08
JP7134294B2 (ja) 2022-09-09
JP2021121597A (ja) 2021-08-26
PL3340973T3 (pl) 2021-06-14
RS61804B1 (sr) 2021-06-30
SI3340973T1 (sl) 2021-07-30
PT3340973T (pt) 2021-01-19
US20180243248A1 (en) 2018-08-30
US10512623B2 (en) 2019-12-24
KR20180059446A (ko) 2018-06-04
HK1257822A1 (en) 2019-11-01
US20170056353A1 (en) 2017-03-02
CA2996520A1 (en) 2017-03-02
WO2017035331A1 (en) 2017-03-02
CA2996520C (en) 2024-11-19
CN108472269A (zh) 2018-08-31
JP2018531280A (ja) 2018-10-25
EP3340973A4 (en) 2019-04-03
EP3340973B1 (en) 2020-10-14
EP3340973A1 (en) 2018-07-04
US20170056352A1 (en) 2017-03-02
HRP20210044T1 (hr) 2021-04-30
US20200138759A1 (en) 2020-05-07

Similar Documents

Publication Publication Date Title
CN108472269B (zh) 具有改进的性质药学上可接受的β-胍基丙酸盐及其用途
JP7383652B2 (ja) Ｂ－ｒａｆキナーゼのマレイン酸塩、結晶形、調整方法、及びその使用
JP2018531280A6 (ja) 改善された特性を有するβ−グアニジノプロピオン酸の薬学的に許容される塩及びその使用
ES3025633T3 (en) New crystalline forms of n-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methvlphenyl)-2(trifluoromethyl)isonicotinamide as raf inhibitors for the treatment of cancer
JP6918824B2 (ja) ２−［（２Ｓ）−１−アザビシクロ［２．２．２］オクタ−２−イル］−６−（３−メチル−１Ｈ−ピラゾール−４−イル）チエノ［３，２−ｄ］ピリミジン−４（３Ｈ）−オン半水和物の結晶形
TW202311259A (zh) 化合物i的新形式及其應用
EP2603503B1 (en) Dabigatran etexilate bismesylate salt, solid state forms and process for preparation thereof
KR20060054300A (ko) 선택적인 사이클린 의존성 키나제 4 억제제로서의이세싸이오네이트 염
CA2909629C (en) Pharmaceutical formulations, processes, solid forms and methods of use relating to 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one
HU231013B1 (hu) Dasatinib sók
EP4685137A1 (en) Solid form of naphthylamine mitophagy inducer, and preparation method therefor, pharmaceutical composition thereof and use thereof
KR20240019116A (ko) (3r)-n-[2-시아노-4-플루오로-3-(3-메틸-4-옥소-퀴나졸린-6-일)옥시-페닐]-3-플루오로-피롤리딘-1-설폰아미드의신규 고체 형태
EA028351B1 (ru) Твердые формы гидрохлорида вемурафениба
EP3023421A1 (en) Crystalline forms of afatinib dimaleate
JP2024509276A (ja) キナーゼ阻害剤の塩及び固体形態
JP2022001598A (ja) Ｔｔｋ阻害剤の固体形態
HK40062831A (en) PHARMACEUTICALLY ACCEPTABLE SALTS OF β-GUANIDINOPROPIONIC ACID WITH IMPROVED PROPERTIES AND USES THEREOF
JP2007277241A (ja) （２Ｒ，Ｚ）−２−アミノ−２−シクロヘキシル−Ｎ−（５−（１−メチル−１Ｈ−ピラゾール−４−イル）−１−オキソ−２，６−ジヒドロ−１Ｈ−［１，２］ジアゼピノ［４，５，６−ｃｄ］インドール−８−イル）アセトアミドの多形体
WO2023164255A1 (en) Crystalline forms of trilaciclib and trilaciclib salts
JP6961348B2 (ja) 置換されたイミダゾピリジニル−アミノピリジン化合物の塩および多型
KR20220088712A (ko) 화합물의 염 및 이의 결정질 형태
CN119684195B (zh) 一种以金刚烷为疏水基团修饰的prmt1蛋白降解剂及其应用
WO2022199699A1 (zh) 含氮稠杂环化合物的盐的晶型及其制备方法和应用
JP2024535857A (ja) 縮合二環系誘導体の薬学的に許容される塩、結晶及びそれらの調製方法
AU2020274362A1 (en) Substituted fluorine-containing imidazole salt compound, preparation method therefor, pharmaceutical composition thereof and use thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information

Address after: New York, United States

Applicant after: Insbona

Address before: New York, United States

Applicant before: RGENIX, Inc.

CB02 Change of applicant information
GR01 Patent grant
GR01 Patent grant